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Abstract
Following the submission of application EFSA-GMO-RX-009 under Regulation (EC) No 1829/2003 from
Bayer CropScience N.V., the Panel on Genetically Modiﬁed Organisms of the European Food Safety
Authority was asked to deliver a scientiﬁc risk assessment on the data submitted in the context of the
renewal of authorisation application for the herbicide-tolerant genetically modiﬁed soybean A2704-12,
for food and feed uses, import and processing, excluding cultivation within the European Union. The
data received in the context of this renewal application contained post-market environmental
monitoring reports, a systematic search and evaluation of literature, updated bioinformatic analyses,
and additional documents or studies performed by or on behalf of the applicant. In addition, the
applicant provided sequence data on the soybean A2704-12 event using material from a commercial
variety currently on the market and intended to be marketed in the coming years. The GMO
Panel assessed these data for possible new hazards, modiﬁed exposure or new scientiﬁc uncertainties
identiﬁed during the authorisation period and not previously assessed in the context of the original
application. The GMO Panel concludes that there is no evidence in the renewal application EFSA-GMO-
RX-009 for new hazards, modiﬁed exposure or scientiﬁc uncertainties that would change the
conclusions of the original risk assessment on soybean A2704-12.
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Summary
Following the submission of application EFSA-GMO-RX-009 under Regulation (EC) No 1829/2003
from Bayer CropScience N.V., the Panel on Genetically Modiﬁed Organisms of the European Food
Safety Authority (GMO Panel) was asked to deliver a scientiﬁc risk assessment on the data submitted
in the context of the renewal of authorisation application for the herbicide-tolerant genetically modiﬁed
soybean A2704-12. The scope of renewal application EFSA-GMO-RX-009 is for placing on the market of
products containing, consisting of, or produced from soybean A2704-12, excluding cultivation within
the European Union.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-RX-009,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications. The data received in the context of the renewal application EFSA-
GMO-RX-009 contained: post-market environmental monitoring reports, an evaluation of the literature
retrieved by a systematic search, updated bioinformatics analyses, and additional studies performed by
or on behalf of the applicant. In addition, the applicant provided sequence data on the soybean
A2704-12 event using material from a commercial variety currently on the market and intended to be
marketed in the coming years. The GMO Panel assessed these data for possible new hazards, modiﬁed
exposure or new scientiﬁc uncertainties identiﬁed during the authorisation period and not previously
assessed in the context of the original application.
The GMO Panel concludes that there is no evidence in renewal application EFSA-GMO-RX-009 for
new hazards, modiﬁed exposure or scientiﬁc uncertainties that would change the conclusions of the
original risk assessment on soybean A2704-12 (EFSA, 2007).
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1. Introduction
1.1. Background
On 3 November 2017, the European Food Safety Authority (EFSA) received from the European
Commission (DG SANTE) application EFSA-GMO-RX-009 by Bayer CropScience N.V. for the renewal of
authorisation of genetically modiﬁed (GM) soybean A2704-12 (Unique Identiﬁer ACS-GMØØ5–3) for the
placing on the market of products containing, consisting of, or produced from this GM soybean for
import and processing submitted within the framework of Regulation (EC) No 1829/20031. Before
sending the application to EFSA, the European Commission conﬁrmed whether the data submitted in
the context of this renewal application were in line with the legal requirements laid down in Articles 11
and 23 of Regulation (EC) No 1829/2003.
After receiving application EFSA-GMO-RX-009, and in accordance with Articles 5(2)(b) and 17(2)(b)
of Regulation (EC) No 1829/2003, EFSA informed Member States and made the summary of the
application available to the public on the EFSA website.2
On 9 March 2018, EFSA declared the application valid in accordance with Articles 6(1) and 18(1) of
Regulation (EC) No 1829/2003. EFSA made the valid application available to Member States and the
European Commission, and consulted nominated risk assessment bodies of Member States, including
national Competent Authorities within the meaning of Directive 2001/18/EC following the requirements
of Articles 6(4) and 18(4) of Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. Member
States had three months after the opening of the Member State commenting period (until
9 June 2018) to make their opinion known.
Following the submission of application EFSA-GMO-NL-2005-18 and the publication of the EFSA
scientiﬁc opinion (EFSA, 2007), the placing on the market of soybean A2704-12 for products
containing, consisting of, or produced from this GM soybean, excluding cultivation in the European
Union, was authorised by Commission Decision 2008/837/EC3. A copy of this authorisation was
provided by the applicant.4
EFSA requested additional information on 26 March 2018 and 8 May 2018. The applicant submitted
their replies on 27 April 2018 and 19 June 2018, respectively.
In giving its scientiﬁc opinion to the European Commission, the Member States and the applicant,
and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has
endeavoured to respect a time limit of six months from the acknowledgement of the valid application.
As additional information was requested by the Panel on Genetically Modiﬁed Organisms of the
European Food Safety Authority (GMO Panel), the time limit of 6 months was extended accordingly, in
line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc risk assessment on the data submitted in the
context of the renewal of authorisation application for the placing on the market of products
containing, consisting of, or produced from GM soybean A2704-12, in accordance with Articles 11 and
23 of Regulation (EC) No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food and feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2017-00721
3 COMMISSION DECISION of 8 September 2008 authorising the placing on the market of products containing, consisting of, or
produced from genetically modiﬁed soybean A2704-12 (ACS-GMØØ5-3) pursuant to Regulation (EC) No 1829/2003 of the
European Parliament and of the Council. Ofﬁcial Journal of the European Union L 247/50, 16.9.2008.
4 Dossier: Soybean A2704-12 renewal – Annex 1.
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The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food and feed and/or food and feed produced from it), which are matters related to risk
management.
2. Data and methodologies
2.1. Data
The data for application EFSA-GMO-RX-009 provided by the applicant at the time of submission, or
in reply to requests for additional information, are speciﬁed below.
The applicant submitted sequence data on soybean A2704-12 single event5 derived from material
of an early generation (T4) of soybean A2704-12 (fourth generation after the original transformant)
and from material of a commercially available soybean A2704-12 variety currently on the market and
indicated that these sequences are identical.
The applicant clariﬁed that the soybean A2704-12 commercial variety has been available on the
market since 2016 and is intended to be marketed in the coming years. The applicant also clariﬁed
that the A2704-12 event sequence reported in this renewal application is the sequence submitted in
the original application EFSA-GMO-NL-2005-18 (EFSA, 2007), corrected for eight nucleotides, two of
which affect newly created open reading frames (ORFs) within the insert and spanning the junction
sites (EFSA, 2018).
2.1.1. Post-market monitoring reports6
Based on the outcome of the initial food and feed risk assessment, a post-market monitoring plan
for monitoring of GM food and feed was not required by the authorisation decision. The
implementation of a post-market environmental monitoring (PMEM) plan, consisting of a general
surveillance plan to check for any adverse effects on the environment arising from soybean A2704-12,
was a condition for the authorisation. As no potential adverse environmental effects were identiﬁed in
the environmental risk assessment of soybean A2704-12 (EFSA, 2007), case-speciﬁc monitoring was
not considered necessary by the GMO Panel.
The applicant provided eight annual PMEM reports covering a reporting period from
September 2008 to June 2016. The annual PMEM plans submitted by the applicant included (1) the
description of a centralised system established by EuropaBio for the collection of information recorded
by various operators (federations involved in soybean seeds import and processing) on any observed
adverse effect(s) on human health and the environment arising from handling of soybean possibly
containing soybean A2704012; (2) the reports of the surveillance activities conducted by such
operators; and (3) the review of relevant scientiﬁc peer-reviewed studies retrieved from literature
searches.
2.1.2. Systematic search and evaluation of literature7
In addition to the eight separate literature searches provided as part of the annual PMEM reports,
the applicant performed a systematic literature search for soybean A2704012 and the newly expressed
phosphinothricin N-acetyltransferase (PAT) protein covering the period from 1 September 2007 till
10 January 2018, in accordance with the recommendations on literature searching outlined in EFSA
(2010, 2017a).
Searches against electronic bibliographic databases and internet searches to specialist databases
were performed to identify relevant publications. Altogether, 564 publications were retrieved. After
applying the eligibility/inclusion criteria deﬁned a priori by the applicant, six publications were identiﬁed
as relevant for food and feed safety assessment, molecular characterisation and environmental safety
assessment. The list of relevant publications is provided in Appendix A.
5 Dossier: Soybean A2704-12 renewal – Section 3.
6 Dossier: Soybean A2704-12 renewal – Section 2.
7 Dossier Soybean A2704-12 renewal – Section 3a; additional information: 27/4/2018.
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2.1.3. Updated bioinformatic data8
At the time of submission of the renewal dossier, the applicant provided a complete bioinformatic
dataset for the soybean A2704-12 event (using the corrected sequence) including an analysis of the
insert and ﬂanking sequences, an analysis of the potential similarity to allergens and toxins of the
newly expressed protein and of all possible ORFs within the insert and spanning the junction sites, and
an analysis of possible horizontal gene transfer (EFSA, 2017b). The outcome of the updated
bioinformatic analyses is presented in Section 3.3. On 8 May 2018, EFSA requested supplementary
information on the partial deletion of the endogenous gene previously reported in the frame of the
original application EFSA-GMO-NL-2005-18. On 19 June 2018, the applicant provided the
supplementary information which included information on the function of the interrupted endogenous
gene and a risk assessment of its interruption with respect to the agronomic–phenotypic characteristics
and composition of soybean A2704-12.
2.1.4. Additional documents or studies provided by the applicant9
The applicant provided an overview on the worldwide approvals of soybean A2704-12 and a list
containing the summaries of all studies performed by or on behalf of the applicant over the course of
the authorisation period and not previously submitted to the EU (Appendix B).
The relevance of the listed studies for molecular characterisation, human and animal safety and the
environment was assessed by the applicant.
On 26 March 2018, the GMO Panel requested the applicant to provide the full study reports of ﬁve
of these studies considered potentially relevant for safety assessment. The applicant submitted the
requested information on 27 April 2018.
2.1.5. Overall assessment as provided by the applicant10
The applicant provided an overall assessment concluding that information provided in the
application for renewal of authorisation of soybean A2704-12 for food and feed use and processing in
the EU does not change the outcome of the original risk assessment (EFSA, 2007).
2.1.6. Monitoring plan and proposal for improving the conditions of the original
authorisation11
The applicant indicated in the dossier that the environmental monitoring plan is appropriate and
does not need any changes.
2.2. Methodologies
The GMO Panel assessed the application for renewal of the authorisation of soybean A2704-12 for
food and feed uses, import and processing in accordance with Articles 11 and 23 of Regulation (EC)
No 1829/2003. The GMO Panel took into account the requirements described in its guideline for the
risk assessment of renewal applications of GM food and feed authorised under Regulation (EC)
No 1829/2003 (EFSA GMO Panel, 2015).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion12 and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Evaluation of the post-market monitoring reports
During the general surveillance activities covering the authorisation period of soybean A2704-12, no
adverse effects were reported by the applicant.
8 Dossier: Soybean A2704-12 renewal – Section 3b; additional information: 19/6/2018.
9 Dossier: Soybean A2704-12 renewal – Section 3c; additional information: 27/4/2018.
10 Dossier: Soybean A2704-12 renewal – Section 4.
11 Dossier: Soybean A2704-12 renewal – Section 5.
12 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2018-00992
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3.2. Evaluation of the systematic search and evaluation of literature
The GMO Panel assessed the applicant’s literature searches on soybean A2704-12. Although the
overall quality of the performed literature searches is acceptable, the GMO Panel considers that future
searches could be improved. The GMO Panel therefore recommends the applicant for future searches
to:
• ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientiﬁc terminology, common typos, translation issues);
• include trait terms;
• include controlled vocabulary (subject indexing) in the searches when available (in addition
to/combination with text words);
• use wider proximity operators (5W).
The GMO Panel acknowledges that no publications raising a safety concern for human and animal
health and the environment which would change the original risk assessment conclusions on soybean
A2704-12 (EFSA, 2007) have been identiﬁed by the applicant.
3.3. Evaluation of the updated bioinformatic data
The results of the updated bioinformatic analyses of soybean A2704-12 using the corrected event
sequence (EFSA, 2018) conﬁrm the previous conclusions on the partial deletion of an endogenous
gene. Based on the information from updated databases submitted in the frame of this renewal
application, this gene is identiﬁed as SEOe, a member of the sieve element occlusion (SEO) multigene
family encoding for Glycine max SEO proteins. The SEOe gene is one of four genes in subgroup 5 of
the SEO gene family, thereby indicating that functional redundancy for this gene in the soybean
genome is likely. In addition, the original agronomic, phenotypic and compositional analyses of
soybean A2704-12 (including endpoints that may be relevant to the reported biological role of SEO
proteins in photoassimilate translocation via the phloem network such as plant height, yield and ﬁber
content) did not indicate relevant differences as compared to the non-GM comparator.
Analyses of the amino acid sequence of the newly expressed PAT protein reveal no signiﬁcant
similarities to toxins or allergens. In addition, bioinformatic analyses of the newly created ORFs (using
the corrected event sequence) within the insert or spanning the junctions with genomic DNA reveal no
signiﬁcant similarities to toxins and allergens.
Updated bioinformatic analyses of the recombinant DNA present in soybean A2704-12 reveal
sufﬁcient sequence identity at both ends of the inserted cassette by the disrupted bla gene. This could
facilitate double homologous recombination with bla genes as they can occur in environmental
bacteria. The recombination event, however, would result in the disruption of such genes in the
recipients. In addition, the insertion of a pat gene codon-optimised for plants regulated by a plant
virus promoter would probably lack PAT activity in potential recipient bacteria. Therefore, bacteria in
which the described double homologous recombination would occur would lose their antibiotic
resistance and acquire a plant codon-optimised pat gene for which a selective advantage, compared to
natural variants of pat genes as they occur in environmental bacteria, cannot be expected. The results
of updated bioinformatic analyses conﬁrm the previous conclusions that the unlikely, but theoretically
possible, horizontal transfer of recombinant genes from soybean A2704-12 to bacteria does not raise
any environmental safety concern (EFSA, 2007).
3.4. Evaluation of the additional documents or studies provided by the
applicant
The GMO Panel evaluated the summary and/or full study reports of the additional studies provided
and (Appendix B). This new information does not raise any concern for human and animal health and
the environment, which would change the original risk assessment conclusions on soybean A2704-12.
3.5. Evaluation of the overall assessment as provided by the applicant
The GMO Panel evaluated the overall assessment provided by the applicant and conﬁrms that there
is no evidence in renewal application EFSA-GMO-RX-009 indicating new hazards, relevant changes in
exposure or scientiﬁc uncertainties that would change previous conclusions on soybean A2704-12.
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3.6. Evaluation of the monitoring plan and proposal for improving the
conditions of the original authorisation
The PMEM plan covers general surveillance of imported GM plant material, including soybean
A2704-12. This general surveillance is coordinated by EuropaBio and implemented by selected
operators (federations involved in soybean seeds import and processing). In addition, the applicant
reviews relevant scientiﬁc publications retrieved from literature searches on an annual basis. The GMO
Panel is of the opinion that the scope of the plan provided by the applicant is consistent with the
scope of soybean A2704-12, but reminds that monitoring is related to risk management, and thus, the
ﬁnal adoption and implementation of the PMEM plan falls outside the mandate of EFSA.
4. Conclusions
Based on the data provided, the GMO Panel concludes that there is no evidence in the renewal
application EFSA-GMO-RX-009 for new hazards, modiﬁed exposure or scientiﬁc uncertainties that
would change the conclusions of the original risk assessment on soybean A2704–12 (EFSA, 2007).
Documentation provided to EFSA
1) Letter from the European Commission to EFSA received on 3 November 2017 for the
continued marketing of genetically modiﬁed soybean A2704-12 in accordance with articles 11
and 23 of Regulation (EC) No 1829/2003 by Bayer CropScience N.V. (EFSA-GMO-RX-009).
2) Acknowledgement letter, dated 7 November 2017, from EFSA to the European Commission.
3) Letter from EFSA to applicant dated 15 December 2017 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 16 February 2018 providing additional
information under completeness check.
5) Letter from EFSA to applicant dated 9 March 2018 delivering the ‘Statement of Validity’ for
application EFSA-GMO-RX-009.
6) Letter from EFSA to applicant dated 26 March 2018 requesting additional information and
stopping the clock.
7) Letter from applicant to EFSA received on 27 April 2018 providing additional information.
8) Letter from EFSA to applicant dated 30 April 2018 re-starting the clock from 27 April 2018.
9) Letter from EFSA to applicant dated 8 May 2018 requesting additional information and
stopping the clock.
10) Letter from applicant to EFSA received on 19 June 2018 providing additional information.
11) Letter from EFSA to applicant dated 19 June 2018 re-starting the clock from 19 June 2018.
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Abbreviations
GM genetically modiﬁed
GMO genetically modiﬁed organisms
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
ORFs open reading frames
PAT phosphinothricin N-acetyltransferase
PMEM post-market environmental monitoring
SEO sieve element occlusion
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Appendix A – List of relevant publications identiﬁed by the applicant
through the systematic literature search (1/9/2007–10/1/2018)
Reference
Fard NA et al., 2013. In silico allergenicity assessment of novel proteins derived from GMHR crops. Ortuno F and
Rojas I [Eds]. Proceedings IWBBIO.
Fard NA, Minuchehr Z and Mousavi A, 2013. Allergenicity study of genetically modiﬁed herbicide resistant crops
(bioinformatics assessment). Bulletin of Environment, Pharmacology and Life Sciences, 2, 24–32.
Nagy A, Pauk J, Takacs K and Gelencser E, 2008. Nutritional evaluation of the proteins of broad range herbicide
resistant spring wheat (Triticum aestivum L.) lines. II. Resistance to digestion of marker proteins in rat model.
Acta Alimentaria, 37, 159–166.
Oh J, Ko M and Lee H, 2009. Evaluation for allergenicity for genetically modiﬁed organic foods. Journal of Allergy
and Clinical Immunology, 123, S244.
Schafer BW, Embrey SK and Herman RA, 2016. Rapid simulated gastric ﬂuid digestion of in-seed/grain proteins
expressed in genetically engineered crops. Regulatory Toxicology and Pharmacology, 81, 106–112.
Verma AK, Misra A, Subash S, Das M and Dwivedi PD, 2011. Computational allergenicity prediction of transgenic
proteins expressed in genetically modiﬁed crops. Immunopharmacology and Immunotoxicology, 33, 410–422.
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Appendix B – List of additional studies performed by or on behalf of the
applicant over the course of the authorisation period and not previously
submitted to the EU with regard to the evaluation of the safety of the food
and feed for humans, animal or the environment from soybean A2704-12
Study identiﬁcation Title
M–413199-01-1 Agronomic characteristics of glufosinate-tolerant soybean A2704-12, USA, 2006
M-534302-01-1 Structural stability analysis of early and recent generations of Glycine max A2704-12
M-540738-01-1 A2704-12 soybean - Inheritance of the insert over two generations
M-131221-04-1(a) PAT/pat protein: Heat stability study
M-214021-03-1 PAT/pat protein: in vitro digestibility study in human simulated intestinal ﬂuid
M-214025-05-1(a) PAT/pat protein - In vitro digestibility study in human simulated gastric ﬂuid
M-344158-01-1(a) PAT protein (encoded the pat gene) - Acute toxicity (48 hours) to rainbow trout
(Oncorhynchus mykiss) by intraperitoneal injection
M-395296-01-1 Measurement of PAT protein in soybean oil samples using the QualiPlate Kit for
PAT from EnviroLogix
M-475440-01-1(a) PAT/pat protein - Acute toxicity by oral gavage in mice
M-500889-01-1(a) The effect of temperature on microbially-produced PAT/pat as assessed by ELISA
(a): Studies for which the full report was requested by the GMO Panel.
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